Amgen, Kyowa Kirin announce long-term Phase 3 data for eczema drug

6 hours ago 1
Atopic dermatitis

Amgen (NASDAQ:AMGN) and Kyowa Kirin (OTCPK:KYKOF) announced on Tuesday that their antibody therapy rocatinlimab is safe and effective in the long term, based on data from a Phase 3 trial for patients with atopic dermatitis, a skin condition also

Recommended For You

More Trending News

Read Entire Article